Observational Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 21, 2021; 27(11): 1076-1089
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1076
Table 1 Demographic and clinical characteristics of inflammatory bowel disease patients

CD (n = 168)
UC (n = 143)
Age, yr, median (IQR)39 (IQR: 28-52.75)45 (IQR: 33-54)
Gender, n (%)
Female71 (42.26)64 (44.76)
Male97 (57.74)79 (55.24)
BMI, n (%)
Normal94 (55.95)81 (56.64)
Thinnish60 (35.71)37 (25.88)
Overweight11 (6.55)25 (17.48)
Obesity3 (1.79)0 (0)
Marital status, n (%)
Unmarried58 (34.52)14 (9.79)
Married105 (62.50)126 (88.11)
Divorced3 (1.79)3 (2.10)
Death of a spouse2 (1.19)0 (0)
Employment status, n (%)
No work16 (9.52)13 (9.09)
Full time117 (69.64)91 (63.64)
Retired15 (8.93)35 (24.48)
Long-term sick leave1 (0.60)3 (2.10)
Students19 (11.31)1 (0.69)
Medical insurance, n (%)
Yes151 (89.88)130 (90.91)
No17 (10.12)13 (9.09)
Education, n (%)
Primary school or below14 (8.33)20 (13.99)
Junior high school34 (20.24)36 (25.17)
Senior high school32 (19.05)41 (28.67)
Junior college or Undergraduate81 (48.21)42 (29.37)
Master degree or above7 (4.17)4 (2.80)
Montreal classification, n (%)
L1 ileal38 (22.62)
L2 colonic14 (8.33)
L3 ileocolonic72 (42.86)
L4 upper gastrointestinal tract11 (6.55)
L1 + L413 (7.74)
L3 + L420 (11.90)
E1 proctitis37 (25.88)
E2 left-sided UC40 (27.97)
E3 extensive UC66 (46.15)
Disease activity: n (%)
Remission100 (59.52)51 (35.66)
Mild activity26 (15.48)43 (30.07)
Moderate activity31 (18.45)37 (25.88)
Severe activity11 (6.55)12 (8.39)
Duration of disease, yr, median (IQR)5.50 (IQR, 2-11)5 (IQR, 2.3-13)
Current medication, n (%)
5-ASA19 (11.31)88 (61.54)
IS42 (25)30 (20.98)
5-ASA + IS22 (13.09)8 (5.59)
Biological preparation45 (26.79)5 (3.50)
Biological preparation + IS34 (20.24)8 (5.59)
Other6 (3.57)4 (2.80)
IBD related surgery, n (%)
No80 (47.62)129 (90.21)
Yes88 (52.38)14 (9.79)